A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD).

Trial Profile

A Multicenter, Open Label, Escalating Dose Study to Assess the Tolerability and the Safety and to Explore the Efficacy and the Pharmacokinetics of ND0801 in Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD).

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2012

At a glance

  • Drugs Nictoine/opipramol (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Nov 2012 Planned end date changed from 1 Apr 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Nov 2010 Status changed from not yet recruiting to recruiting, according to a NeuroDerm media release.
    • 12 Oct 2010 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top